πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 29 of 173

  1. US 11389386

    Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11390605

    Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11389482

    Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11382890

    Prevention of rosacea inflammation

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11384076

    Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11382955

    Long-acting VEGF inhibitors for intraocular neovascularization

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11384350

    Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11382989

    Engineered microbial population

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11382899

    Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11382885

    Compositions for treating fungal and bacterial biofilms and methods of using the same

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11382929

    Compositions and methods to treat disease

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11382897

    Therapeutic combination for treatment of cerebellar ataxia

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11376324

    Sting activating nanovaccine for immunotherapy

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11376311

    Methods of treating microbial infection and inflammation

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11377646

    Modified cells comprising CRISPR systems

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11377491

    Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11376346

    Extracellular matrix for treating pelvic floor disorders and skeletal muscle degeneration

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11376247

    Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11376226

    Biodegradable polymer microparticle containing steroid drug and preparation method therefor

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11377659

    Short hairpin RNA (shRNA734) and use of same to positively select and eliminate genetically modified cells

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11377451

    Compositions and methods for treating cancer

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11376221

    Polymer particles for neutrophil injury

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11369683

    Systems and methods for targeted imaging and ablation of cardiac cells

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11369688

    Hybrid telodendrimers

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11370757

    Photocleavable nitroindoline-based crosslinkers

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11369716

    Reparative cell isolation and delivery

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11369644

    Microbial consortia

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11369566

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11370825

    Polypeptides, cells, and methods involving engineered CD16

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11370786

    GLS1 inhibitors for treating disease

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11371062

    RNA-guided nucleic acid modifying enzymes and methods of use thereof

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11370769

    TRPC5 inhibitors and methods of using same

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11369575

    PPARΞ± agonist compositions and methods of use

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11364293

    Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11365183

    Eicosanoid derivatives

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11364260

    Methods and compositions for administration of iron

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11365250

    Compositions and methods for cancer therapy

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11365413

    Inhibition of poly(A) binding protein and the treatment of pain

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11365189

    Heterocyclic inhibitors of tyrosine kinase

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11364197

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11366121

    Specific GNAI:GIV interaction screening assays, methods and compositions

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11357872

    Imaging neurotransmitters in vivo using functionalized carbon nanotubes

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11357801

    Methods for treating autism spectrum disorder and associated symptoms

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11357817

    Immunoproteasome inhibitor

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11357736

    Detoxification using nanoparticles

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11357783

    Conjugate of finasteride with peptide

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11357848

    Methods of rational nicotine hapten design and uses thereof

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11358947

    Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.